ISRCTN44890666已完成未知
VITAL Germany (Valdoxan® improves treatment of depression and daytime activity in real life) : an observational prospective multicentre study
Servier Deutschland GmbH (Germany)0 个研究点目标入组 3,005 人开始时间: 2011年3月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 3,005
研究概览
简要总结
2016 results in: https://www.ppt-online.de/archiv/verzeichnis/2016/04.html (added 13/09/2019)
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •Adult patients with episodes of major depression
排除标准
- •Does not meet inclusion criteria
研究者
相似试验
已完成
4 期
VIVALDI: Valdoxan® improves depressive symptoms and normalises circadian rhythmsEpisodes of major depressionMental and Behavioural DisordersDepressive episodeISRCTN49411996Servier Deutschland GmbH (Germany)8,000
已完成
不适用
VIVID-ONValdoxan® improves vitality in depression with anhedoniaF32Depressive episodeDRKS00011602Servier Deutschland GmbH970
已完成
1 期
MUK sixHaematological OncologyDisease: MyelomaCancerMultiple myelomaISRCTN59395590niversity of Leeds (UK)54
已完成
4 期
VIVALDI Praxis: Valdoxan improves depressive symptoms and normalizes circadian rhythmsEpisodes of major depressionMental and Behavioural DisordersRecurrent depressive disorderISRCTN18801971Servier Deutschland GmbH (Germany)3,600
Unknown
1 期
Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple MyelomaMultiple MyelomaNCT02145715Prof Jamie Cavenagh54